556 related articles for article (PubMed ID: 15518071)
1. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
[TBL] [Abstract][Full Text] [Related]
2. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR; Kanwar YS
FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
[TBL] [Abstract][Full Text] [Related]
3. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress.
Mason RP; Walter MF; Jacob RF
Circulation; 2004 Jun; 109(21 Suppl 1):II34-41. PubMed ID: 15173061
[TBL] [Abstract][Full Text] [Related]
4. Antioxidative effects of statins.
Adam O; Laufs U
Arch Toxicol; 2008 Dec; 82(12):885-92. PubMed ID: 18670762
[TBL] [Abstract][Full Text] [Related]
5. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
6. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Ito MK; Talbert RL; Tsimikas S
Pharmacotherapy; 2006 Jul; 26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. PubMed ID: 16803418
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of HMG-CoA reductase inhibitors.
Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
[TBL] [Abstract][Full Text] [Related]
8. Statins: a treatment option for chronic heart failure?
von Haehling S; Okonko DO; Anker SD
Heart Fail Monit; 2004; 4(3):90-7. PubMed ID: 15772704
[TBL] [Abstract][Full Text] [Related]
9. Statins and endothelial dysfunction.
Larose E; Ganz P
Semin Vasc Med; 2004 Nov; 4(4):333-46. PubMed ID: 15861315
[TBL] [Abstract][Full Text] [Related]
10. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
[TBL] [Abstract][Full Text] [Related]
11. [Statins and brain protection mechanisms].
Tapia-Perez H; Sanchez-Aguilar M; Torres-Corzo J; Rodriguez-Leyva I; Herrera-Gonzalez LB
Rev Neurol; 2007 Sep 16-30; 45(6):359-64. PubMed ID: 17899518
[TBL] [Abstract][Full Text] [Related]
12. The effects of statins on endothelium, inflammation and cardioprotection.
Elrod JW; Lefer DJ
Drug News Perspect; 2005 May; 18(4):229-36. PubMed ID: 16034478
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation.
Arnaud C; Mach F
Arch Mal Coeur Vaiss; 2005 Jun; 98(6):661-6. PubMed ID: 16007821
[TBL] [Abstract][Full Text] [Related]
14. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
Fujita R; Matsushima T
Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
[TBL] [Abstract][Full Text] [Related]
15. Microcirculation as a target for the anti-inflammatory properties of statins.
Scalia R; Stalker TJ
Microcirculation; 2002 Dec; 9(6):431-42. PubMed ID: 12483541
[TBL] [Abstract][Full Text] [Related]
16. Potential vascular benefits of statins.
Kinlay S
Am J Med; 2005 Dec; 118 Suppl 12A():62-7. PubMed ID: 16356810
[TBL] [Abstract][Full Text] [Related]
17. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
18. Statins: multiple mechanisms of action in the ischemic brain.
Cimino M; Gelosa P; Gianella A; Nobili E; Tremoli E; Sironi L
Neuroscientist; 2007 Jun; 13(3):208-13. PubMed ID: 17519364
[TBL] [Abstract][Full Text] [Related]
19. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
20. Statins and their role in vascular protection.
Mason JC
Clin Sci (Lond); 2003 Sep; 105(3):251-66. PubMed ID: 12793855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
